Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL: Immune Globulin Intravenous (Human), 10% Solution
DRUG: Immune Globulin Subcutaneous (Human), 20% Solution

Sponsor

Baxalta now part of Shire